Literature DB >> 9013942

Plasmin-induced proteolysis of tenascin-C: modulation by T lymphocyte-derived urokinase-type plasminogen activator and effect on T lymphocyte adhesion, activation, and cell clustering.

D Gundersen1, C Trân-Thang, B Sordat, F Mourali, C Rüegg.   

Abstract

Proteolysis and remodeling of the extracellular matrix occur physiologically in processes such as tissue morphogenesis and repair and may participate in the regulation of complex cell functions, including proliferation and differentiation. While matrix degradation appears to be relevant to T lymphocyte migration through tissues, little is known about whether degraded matrix affects T lymphocyte function. We have studied the interaction between T lymphocytes and tenascin-C (TN-C), a matrix protein we have previously reported to inhibit T lymphocyte activation, in the context of plasmin-induced degradation. Here we report that plasmin efficiently cleaves TN-C. Peripheral blood T lymphocytes stimulated with phorbol ester, anti-CD28, or anti-CD3 Ab, induce, within 24 to 48 h, a strong plasminogen-dependent proteolysis of TN-C. We demonstrate that stimulated T lymphocytes activate plasminogen by secreting the urokinase-type plasminogen activator (u-PA). Plasminogen activation by T lymphocyte-derived u-PA occurs efficiently in fluid phase in the absence of cells. We investigate the consequences of plasmin-induced proteolysis on three of the effects of TN-C in relation to lymphocyte functions. Plasmin proteolysis converts TN-C from a nonadhesive into an adhesive substrate for T lymphocytes and abolishes its aggregating activity on PBMC. In contrast, the inhibitory effect of TN-C on T lymphocyte activation remains unaffected. These observations demonstrate that stimulated T lymphocytes induce plasminogen-dependent proteolysis of TN-C by secreting u-PA and suggest that proteolysis of TN-C may represent a mechanism by which to regulate some of its effects on T lymphocyte functions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9013942

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Tenascins and the importance of adhesion modulation.

Authors:  Ruth Chiquet-Ehrismann; Richard P Tucker
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-05-01       Impact factor: 10.005

2.  Urokinase-deficient mice fail to generate a type 2 immune response following schistosomal antigen challenge.

Authors:  Margaret R Gyetko; Sudha Sud; Stephen W Chensue
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

3.  Urokinase-type plasminogen activator in inflammatory cell recruitment and host defense against Pneumocystis carinii in mice.

Authors:  J M Beck; A M Preston; M R Gyetko
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

4.  Matricellular proteins: a sticky affair with cancers.

Authors:  Han Chung Chong; Chek Kun Tan; Royston-Luke Huang; Nguan Soon Tan
Journal:  J Oncol       Date:  2012-02-09       Impact factor: 4.375

5.  The plasminogen activator system: involvement in central nervous system inflammation and a potential site for therapeutic intervention.

Authors:  Devorah Gur-Wahnon; Tehila Mizrachi; Florence-Yehudith Maaravi-Pinto; Athanasis Lourbopoulos; Nikolaos Grigoriadis; Abd-Al Roof Higazi; Talma Brenner
Journal:  J Neuroinflammation       Date:  2013-10-11       Impact factor: 8.322

Review 6.  Fibrinolytic Serine Proteases, Therapeutic Serpins and Inflammation: Fire Dancers and Firestorms.

Authors:  Jordan R Yaron; Liqiang Zhang; Qiuyun Guo; Shelley E Haydel; Alexandra R Lucas
Journal:  Front Cardiovasc Med       Date:  2021-03-25

Review 7.  Cell surface remodeling by plasmin: a new function for an old enzyme.

Authors:  Elena I Deryugina; James P Quigley
Journal:  J Biomed Biotechnol       Date:  2012-10-14

8.  The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis.

Authors:  George Perides; Yuzheng Zhuge; Tina Lin; Monique F Stins; Roderick T Bronson; Julian K Wu
Journal:  BMC Cancer       Date:  2006-03-09       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.